Medeor Therapeutics Raises $57 Million In Series B Financing

Company to Use Proceeds to Advance Late-Stage Cellular Immunotherapy Programs in Kidney Transplant Patients SAN MATEO, Calif., Nov. 27, 2017 -- (Healthcare Sales & Marketing Network) -- Medeor Therapeutics, Inc., a clinical-stage biotechnology company ... Personalized Medicine, Venture Capital, Personnel Medeor Therapeutics, immunotherapy

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2043211

Source: HSMN NewsFeed - November 27, 2017 Category: Pharmaceuticals Source Type: news